CG
VIR icon

Cutler Group’s Vir Biotechnology VIR Stock Holding History

Cutler Group’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,200
Closed -$2K – 5571
2022
Q2 		$2K Sell
2,200
-4,100
-65% -$95.7K ﹤0.01% 4394
2022
Q1 		$1K Sell
6,300
-30,600
-83% -$908K ﹤0.01% 5108
2021
Q4 		$19K Buy
+36,900
New +$1.45M ﹤0.01% 3181
2021
Q3 		– Sell
-2,300
Closed -$5K – 6423
2021
Q2 		$5K Sell
2,300
-6,500
-74% -$296K ﹤0.01% 4487
2021
Q1 		$49K Buy
8,800
+1,400
+19% +$75.5K ﹤0.01% 2418
2020
Q4 		$9K Buy
7,400
+5,000
+208% +$163K ﹤0.01% 3290
2020
Q3 		$8K Sell
2,400
-500
-17% -$21.5K ﹤0.01% 3181
2020
Q2 		$17K Buy
2,900
+1,300
+81% +$43.6K ﹤0.01% 2520
2020
Q1 		$11K Buy
+1,600
New +$43K ﹤0.01% 2680

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cutler Group's VIR Position: Q3 2022 in Review

Cutler Group sold out of Vir Biotechnology (VIR) in Q3 2022, closing a stake of 410 shares — an estimated $10.4K sold.

Cutler Group first reported a position in VIR in Q2 2020 and held it in 7 quarters. The position peaked at $474K in Q3 2021. 221 funds tracked by Wall St. Rank hold VIR as of Q3 2022.

  • Cutler Group reported no remaining Vir Biotechnology position as of Q3 2022 after selling out during the quarter.
  • Cutler Group sold 410 Vir Biotechnology shares in Q3 2022, an estimated $10.4K.
  • Cutler Group first reported a position in Vir Biotechnology in Q2 2020 and held it in 7 quarters.
  • Cutler Group's Vir Biotechnology position peaked at $474K in Q3 2021.
  • 221 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2022.

Based on Cutler Group's 13F filing for Q3 2022, filed 25 Oct 2022.